Clinical Research Directory
Browse clinical research sites, groups, and studies.
Celecoxib in Parkinson Disease as Adjuvant Therapy
Sponsor: Tanta University
Summary
Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD
Official title: Evaluating Safety and Efficacy of Celecoxib in Patients With PD.
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-11-20
Completion Date
2026-11-28
Last Updated
2025-12-05
Healthy Volunteers
No
Conditions
Interventions
Levodopa Carbidopa
Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
Celecoxib 200mg
Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)
Locations (1)
Tanta Unuversity
Tanta, Egypt